[{"address1": "The Mediaworks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 647, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 60, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 2520222, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Driggs", "age": 48, "title": "Senior VP of Legal Affairs & General Counsel and Secretary", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher  Williams", "age": 44, "title": "Chief Business Officer", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthias  Will M.D.", "age": 51, "title": "Senior VP & Chief Development Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 52, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert F. Dolski", "age": 54, "title": "Senior VP & CFO", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 59, "title": "Senior VP & COO", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  McIlvenny", "age": 45, "title": "Senior VP of Finance & Chief Accounting Officer", "yearBorn": 1979, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Miranda  Neville", "title": "Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.23, "open": 1.23, "dayLow": 1.2, "dayHigh": 1.245, "regularMarketPreviousClose": 1.23, "regularMarketOpen": 1.23, "regularMarketDayLow": 1.2, "regularMarketDayHigh": 1.245, "payoutRatio": 0.0, "beta": 2.002, "forwardPE": -1.6849315, "volume": 1681570, "regularMarketVolume": 1681570, "averageVolume": 3570120, "averageVolume10days": 2613130, "averageDailyVolume10Day": 2613130, "bid": 1.21, "ask": 1.24, "bidSize": 24, "askSize": 24, "marketCap": 327356224, "fiftyTwoWeekLow": 1.105, "fiftyTwoWeekHigh": 3.45, "allTimeHigh": 53.24, "allTimeLow": 1.105, "priceToSalesTrailing12Months": 6.40268, "fiftyDayAverage": 1.4919, "twoHundredDayAverage": 1.762325, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 285123232, "profitMargins": 0.0, "floatShares": 110710284, "sharesOutstanding": 266143286, "sharesShort": 11981268, "sharesShortPriorMonth": 11487493, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.045, "heldPercentInsiders": 0.18086, "heldPercentInstitutions": 0.73127997, "shortRatio": 4.34, "shortPercentOfFloat": 0.059299998, "impliedSharesOutstanding": 266143286, "bookValue": 0.997, "priceToBook": 1.2337011, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -224802000, "trailingEps": -0.82, "forwardEps": -0.73, "enterpriseToRevenue": 5.577, "enterpriseToEbitda": -1.077, "52WeekChange": -0.5872483, "SandP52WeekChange": 0.09209216, "quoteType": "EQUITY", "currentPrice": 1.23, "targetHighPrice": 13.0, "targetLowPrice": 5.0, "targetMeanPrice": 9.63333, "targetMedianPrice": 10.0, "recommendationMean": 1.1, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 367412992, "totalCashPerShare": 1.381, "ebitda": -264679008, "totalDebt": 325180000, "quickRatio": 5.523, "currentRatio": 6.194, "totalRevenue": 51128000, "debtToEquity": 122.5, "revenuePerShare": 0.192, "returnOnAssets": -0.2299, "returnOnEquity": -0.60559, "grossProfits": -135380992, "freeCashflow": -267752128, "operatingCashflow": -254179008, "grossMargins": -2.6478798, "ebitdaMargins": 0.0, "operatingMargins": -3.37931, "financialCurrency": "USD", "symbol": "AUTL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Autolus Therapeutics plc", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1529674200000, "postMarketChangePercent": 1.0162543, "postMarketPrice": 1.2425, "postMarketChange": 0.0124999285, "regularMarketChange": 0.0, "regularMarketDayRange": "1.2 - 1.245", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 3570120, "fiftyTwoWeekLowChange": 0.125, "fiftyTwoWeekLowChangePercent": 0.11312217, "fiftyTwoWeekRange": "1.105 - 3.45", "fiftyTwoWeekHighChange": -2.22, "fiftyTwoWeekHighChangePercent": -0.6434783, "fiftyTwoWeekChangePercent": -58.72483, "earningsTimestamp": 1762954200, "earningsTimestampStart": 1762954200, "earningsTimestampEnd": 1762954200, "earningsCallTimestampStart": 1762954200, "earningsCallTimestampEnd": 1762954200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.82, "epsForward": -0.73, "epsCurrentYear": -0.90422, "priceEpsCurrentYear": -1.3602885, "fiftyDayAverageChange": -0.26189995, "fiftyDayAverageChangePercent": -0.17554793, "twoHundredDayAverageChange": -0.532325, "twoHundredDayAverageChangePercent": -0.30205837, "corporateActions": [], "postMarketTime": 1763772762, "regularMarketTime": 1763758801, "exchange": "NMS", "messageBoardId": "finmb_562879769", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 1.23, "longName": "Autolus Therapeutics plc", "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "displayName": "Autolus Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-22"}]